ArticleOncotarget2018
Signature of survival: a
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 56 citations in OpenAlex.
- Article
- Assessment of Y-90 Radioembolization Treatment Response for Hepatocellular Carcinoma Cases Using MRI Radiomics.Molecular imaging and radionuclide therapy · 2024Article
- Automated graded prognostic assessment for patients with hepatocellular carcinoma using machine learning.European radiology · 2024Article
- Current research status of transarterial therapies for hepatocellular carcinoma.World journal of gastrointestinal oncology · 2024Article
- [Research progress and prospects of the application of radiographic imaging in the precise diagnosis and treatment of hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Review
- Automated MRI liver segmentation for anatomical segmentation, liver volumetry, and the extraction of radiomics.European radiology · 2024Article
- Nuclear medicine radiomics in digestive system tumors: Concept, applications, challenges, and future perspectives.View (Beijing, China) · 2023Article
- Impact of Tracer Dose Reduction in [18 F]-Labelled Fluorodeoxyglucose-Positron Emission Tomography ([18 F]-FDG)-PET) on Texture Features and Histogram Indices: A Study in Homogeneous Tissues of Phantom and Patient.Tomography (Ann Arbor, Mich.) · 2023Article
- Advancements and Future Outlook of PET/CT-Guided Interventions.Techniques in vascular and interventional radiology · 2023Review
- Radiomics, a Promising New Discipline: Example of Hepatocellular Carcinoma.Diagnostics (Basel, Switzerland) · 2023Review
- Current status and future perspectives of radiomics in hepatocellular carcinoma.World journal of gastroenterology · 2023Review
- Role of Artificial Intelligence in Radiogenomics for Cancers in the Era of Precision Medicine.Cancers · 2022Review
- Radiomics in Oncological PET Imaging: A Systematic Review-Part 2, Infradiaphragmatic Cancers, Blood Malignancies, Melanoma and Musculoskeletal Cancers.Diagnostics (Basel, Switzerland) · 2022Review
- Radiomics of hepatocellular carcinoma: promising roles in patient selection, prediction, and assessment of treatment response.Abdominal radiology (New York) · 2021Review
- State of the Art in Artificial Intelligence and Radiomics in Hepatocellular Carcinoma.Diagnostics (Basel, Switzerland) · 2021Review
- A Systematic Review of PET Textural Analysis and Radiomics in Cancer.Diagnostics (Basel, Switzerland) · 2021Review
- Noninvasive radiomics-based method for evaluating idiopathic central precocious puberty in girls.The Journal of international medical research · 2021Article
- Radiomics of hepatocellular carcinoma.Abdominal radiology (New York) · 2021Review
- Tumor response prediction inEJNMMI physics · 2020Article
- Radiomics in Hepatocellular Carcinoma.Journal of gastrointestinal cancer · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo generate a predictive whole-liver radiomics scoring system for progression-free survival (PFS) and overall survival (OS) in patients undergoing transarterial radioembolization using Yttrium-90 (
resultsThe generated pPET-RadScores were significantly correlated with survival for PFS (median of 11.4 mo [95% confidence interval CI: 6.3-16.5 mo] in low-risk group [PFS-pPET-RadScore < 0.09] vs. 4.0 mo [95% CI: 2.3-5.7 mo] in high-risk group [PFS-pPET-RadScore > 0.09];
conclusionPretreatment
methodsPretreatment
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.